FrancophonIA/ELRC3.0 huggingface dataset:
English: The primary endpoint analysis [quadruple composite of death, MI, urgent target vessel revascularisation (UTVR) and thrombolytic bail-out (TBO) at 48 hours] showed a 37 % relative and 3.9 % absolute reduction in the eptifibatide group (6.6 % events versus 10.5 %, p = 0.0015).
Danish: Den primære effektmålsanalyse [firesidet sammensætning af død, MI, akut revaskularisering af arterien (UTVR) og trombolytisk redningsaktion (TBO) efter 48 timer] viste 37 % relativ og 3,9 % absolut reduktion i eptifibatid-gruppen (6,6 % hændelser imod 10,5 %, p = 0,0015).
English: - if you have recently had bleeding from your stomach, intestines, bladder or other organs, for example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding)
Danish: (angivet i punkt 6) - hvis du for nyligt har haft blødning fra mave, tarm, blære eller andre organer, fx hvis du har observeret unormalt blod i afføring eller urin (undtagen fra menstruationsblødning) i de seneste
English: Patients were randomised to either placebo, eptifibatide 180 microgram/kg bolus followed by a 2.0 microgram/kg/min infusion (180/2.0), or eptifibatide 180 microgram/kg bolus followed by a 1.3 microgram/kg/min infusion (180/1.3).
Danish: Patienterne blev randomiseret til enten placebo, eptifibatid 180 mikrogram/kg bolus efterfulgt af en 2,0 mikrogram/kg/minut infusion (180/2,0) eller eptifibatid 180 mikrogram/kg bolus efterfulgt af en 1,3 mikrogram/kg/minut infusion (180/1,3).
English: All potential bleeding sites, (e.g., catheter insertion sites; arterial, venous, or needle puncture sites; cutdown sites; gastrointestinal and genitourinary tracts) must be observed carefully.
Danish: Alle potentielle blødningssteder (såsom kateterindføringssteder, arterielle, venøse eller kanyle-injektionssteder, operationssteder, gastrointestinale og genitourinare veje) skal observeres omhyggeligt.
English: With delayed provisional eptifibatide administration, the event rates were 10 % vs 11.5 % in patients who received reduced dose and standard dose respectively (p=0.61).
Danish: Ved forsinket provisorisk eptifibatid var hændelsesraterne 10 % versus 11,5 % hos patienter, der fik henholdsvis en nedsat dosis og standarddosis (p = 0,61).
English: Frequencies are defined as very common (≥ 1/10); common (≥ 1/100 to< 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to
Danish: Meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1000 til < 1/100),
English: - Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units.
Danish: - Eptifibatid Accord anbefales kun til anvendelse hos voksne patienter indlagt på hjerteafdeling.
English: In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7 % of eptifibatide -treated patients vs. 4.6 % of placebo-treated patients.
Danish: I undergruppen med patienter, der gennemgik PCI, var observation af større blødninger almindelig, hos 9,7 % af de patienter, der blev behandlet med eptifibatid, sammenlignet med 4,7 % af de placebobehandlede patienter.
English: Eptifibatide Accord 2 mg/ml solution for injection contains 57.96 mg (2.52 mmol) of sodium per maximum daily dose.
Danish: Eptifibatid Accord 2 mg/ml injektionsvæske, opløsning, indeholder 57,96 mg (2,52 mmol) natrium pr. maksimale daglige dosis.
English: Cerebral ischaemia.
Danish: Ikke almindelig Cerebral iskæmi.
English: Fatal bleeding (the majority involved central and peripheral nervous system disorders: cerebral or intracranial haemorrhages); pulmonary haemorrhage, acute profound thrombocytopenia, haematoma.
Danish: Letal blødning (størstedelen involverede det centrale og perifere nervesystem: cerebrale eller intrakranielle blødninger), pulmonale blødninger, akut kraftig trombocytopeni, hæmatom.
English: Therefore, it is not recommended to administer eptifibatide in patients who have previously experienced immune mediated thrombocytopenia with GP IIb/IIIa inhibitors, including eptifibatide.
Danish: Det frarådes derfor at anvende eptifibatid til patienter, som tidligere har fået immunmedieret trombocytopeni som følge af behandling med GP IIb/IIIa-hæmmere, herunder eptifibatid.
English: Concurrent administration of heparin is recommended unless this is contraindicated for reasons such as a history of thrombocytopenia associated with use of heparin (see ‘Heparin administration', section 4.4).
Danish: Samtidig administration af heparin anbefales, medmindre det er kontraindiceret, som ved anamnese med trombocytopeni i forbindelse med anvendelse af heparin (se ”Heparin-indgift” pkt.
English: In patients undergoing PCI, measure the ACT also.
Danish: Mål også ACT hos patienter, der gennemgår PCI.
English: Other medicines and Eptifibatide Accord
Danish: Brug af anden medicin sammen med Eptifibatid Accord
English: In an acute myocardial infarction study involving 181 patients, eptifibatide (in regimens up to a bolus injection of 180 microgram/kg, followed by an infusion up to 2 microgram/kg/min for up to 72 hours) was administered concomitantly with streptokinase (1.5 million units over 60 minutes).
Danish: I et akut myokardieinfarkt-studie med 181 patienter blev eptifibatid givet (i regimer med bolusinjektion på op til 180 mikrogram/kg, efterfulgt af infusion på op til 2 mikrogram/kg/minut i op til 72 timer) sammen med streptokinase (1,5 millioner enheder over 60 minutter).
English: Platelet inhibition was readily reversed, with a return of platelet function towards baseline (> 50 % platelet aggregation) 4 hours after stopping a continuous infusion of 2.0 microgram/kg/min.
Danish: Trombocythæmningen var hurtig reversibel med en genetablering af blodpladefunktionen mod udgangsværdien (> 50 % pladeaggregation) 4 timer efter afbrydelse af en kontinuerlig infusion på 2,0 mikrogram/kg/minut.
English: If PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours.
Danish: Ved PCI forsatte infusionen med eptifibatid i 24 timer efter proceduren med en infusionsvarighed på op til 96 timer.
English: EARLY-ACS trial
Danish: EARLY ACS-forsøget
English: Bleeding (major and minor bleeding including femoral artery access, CABG-related, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
Danish: Blødninger (større og mindre blødninger inklusive femoral arterieindstikssted, CABG-relateret, gastrointestinal, urogenital, retroperitoneal, intrakraniel, hæmatemese, hæmaturi, oral/orofaryngeal, hæmoglobin/hæmatokritreduktion og andre).
English: As demonstrated in clinical trials, the incidence of thrombocytopenia was low, and similar in patients treated with eptifibatide or placebo.
Danish: I kliniske undersøgelser var forekomsten af trombocytopeni lav og på samme niveau hos de patienter, der fik behandling med eptifibatid, og dem, der fik placebo.
English: If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period.
Danish: Hvis du ammer, bør amningen afbrydes i behandlingsperioden.
English: There is limited data with regards to platelet inhibition in patients with renal impairment.
Danish: Der foreligger begrænsede data om trombocythæmning hos patienter med nedsat nyrefunktion.
English: The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment (within the first 72-96 hours) and this reduction was maintained through 6 months, without any significant effect on mortality.
Danish: Reduktionen i hyppigheden af endepunkts-hændelser hos patienter, som fik eptifibatid, optrådte tidligt i behandlingsforløbet (inden for de første 72-96 timer).
English: Because Eptifibatide Accord inhibits platelet aggregation, caution must be employed when it is used with other medicinal products that affect haemostasis, including ticlopidine, clopidogrel, thrombolytics, oral anticoagulants, dextran solutions, adenosine, sulfinpyrazone, prostacyclin, nonsteroidal anti-inflammatory agents, or dypyridamole (see section 4.5).
Danish: Da Eptifibatid Accord hæmmer trombocytaggregationen, skal der udvises forsigtighed, når det anvendes med andre stoffer, der påvirker hæmostasen, inklusive ticlopidin, clopidogrel, trombolytika, orale antikoagulantia, dextranopløsninger, adenosin, sulfinpyrazon, prostacyclin, non-steroide antiinflammatoriske stoffer eller dipyramidol (se pkt.
English: Eptifibatide Accord 0.75 mg/ml solution for infusion contains 77.4 mg (3.37 mmol) of sodium per maximum daily dose.
Danish: Eptifibatid Accord 0,75 mg/ml infusionsvæske, opløsning, indeholder 77,4 mg (3,37 mmol) natrium pr. maksimale daglige dosis.
English: In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
Danish: Hos patienter med moderat nedsat nyrefunktion (kreatininclearance = 30-50 ml/min) blev der opnået en hæmning på 100 % 24 timer efter administration af 2 mikrogram/kg/min.
English: Administer with caution to patients with hepatic impairment in whom coagulation could be affected (see section 4.3, prothrombin time).
Danish: Indgives forsigtigt til patienter med leverinsufficiens, hos hvem koagulationen kan være påvirket (se pkt.
English: - if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section
Danish: - hvis du er allergisk over for eptifibatid eller et af de øvrige indholdsstoffer i Eptifibatid Accord
English: 0.75 mg/ml : 1.72 mg/ml (0.075 mmol/ml) sodium For the full list of excipients, see section 6.1.
Danish: 0,75 mg/ml: 1,72 mg/ml (0,075 mmol/ml) natrium Alle hjælpestoffer er anført under pkt.
English: You must also be given doses of aspirin and heparin (if not contraindicated in your case).
Danish: Du skal også have acetylsalicylsyre og heparin (medmindre du ikke kan tåle disse).
English: PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING UNITS LABEL for 100 ml vial
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE KARTON til 100 ml hætteglas
English: Solution for infusion 100 ml
Danish: Infusionsvæske, opløsning 100 ml
English: The recommended dosage is an intravenous bolus of 180 microgram/kg administered as soon as possible following diagnosis, followed by a continuous infusion of 2 microgram/kg/min for up to 72 hours, until initiation of coronary artery bypass graft (CABG) surgery, or until discharge from the hospital (whichever occurs first).
Danish: Den anbefalede dosering er intravenøs bolus på 180 mikrogram/kg indgivet snarest muligt, efter diagnosen er stillet, efterfulgt af kontinuerlig infusion af 2 mikrogram/kg/minut i op til 72 timer indtil påbegyndelse af koronararterie bypass-kirurgi (CABG) eller indtil udskrivning fra hospitalet (hvad, der forekommer først).
English: Protection of Eptifibatide Accord solution from light is not necessary during administration.
Danish: Det er ikke nødvendigt at beskytte Eptifibatid Accord mod lys under behandlingen.
English: Common side effects These may affect up to 1 in 10 people - inflammation of a vein.
Danish: Dette kan forekomme hos op til 1 ud af 10 patienter - betændelse i en blodåre.
English: The recommended dose is 180 microgram/kg administered as a bolus (rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 72 hours.
Danish: Den sædvanlige dosis er 180 mikrogram/kg indgivet som bolus (hurtig intravenøs injektion), efterfulgt af infusion (drop) på 2 mikrogram/kg/minut i op til 72 timer.
English: Eptifibatide Accord 0.75 mg/ml: Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Danish: Eptifibatid Accord 0,75 mg/ml: Hver ml opløsning indeholder 0,75 mg eptifibatid.
English: Eptifibatide Accord 2 mg/ml: Each ml of solution for injection contains 2 mg of eptifibatide.
Danish: Eptifibatid Accord 2 mg/ml: Hver ml opløsning indeholder 2 mg eptifibatid.
English: Eptifibatide Accord 0.75 mg/ml: The clear, colourless solution is contained in a 100 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Danish: Eptifibatid Accord 0,75 mg/ml: Klar, farveløs opløsning i 100 ml hætteglas, lukket med butylgummiprop og forseglet med ”flip-off”-aluminiumforsegling.
English: EXPIRY DATE
Danish: Udløbsdato:
English: Particularly: blood thinners (oral anticoagulants) or medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except those that you may be given as part of Eptifibatide Accord treatment).
Danish: Især: - blodfortyndende medicin (orale antikoagulantia) - medicin, der forebygger blodpropper, herunder warfarin, dipyridamol, ticlopidin, acetylsalicylsyre
English: These may affect up to 1 in 100 people - reduction in the number of platelets (blood cells necessary for blood clotting).
Danish: Dette kan forekomme hos op til 1 ud af 100 patienter - nedsat antal blodplader (celler, der får blodet til at størkne) - nedsat blodtilførsel til hjernen.
English: Eptifibatide Accord 2 mg/ml: The clear, colourless solution is contained in a 10 ml glass vial, which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Danish: Eptifibatid Accord 2 mg/ml: Klar, farveløs opløsning i 10 ml hætteglas, lukket med butylgummiprop og forseglet med ”flip-off”-aluminiumforsegling.
English: If you get any side effects, talk to your doctor or hospital pharmacist or nurse.
Danish: Hvis du oplever bivirkninger, bør du tale med din læge eller sundhedspersonalet.
English: Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og hætteglasset efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Danish: Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs http://www.ema.europa.eu
English: Eptifibatide Accord solution for infusion must be used in conjunction with Eptifibatide Accord solution for injection.
Danish: Eptifibatid Accord infusionsvæske, opløsning skal anvendes i forening med Eptifibatid Accord injektionsvæske, opløsning.
English: Solution for injection 1 vial of 10 ml
Danish: Injektionsvæske, opløsning 1 hætteglas med 10 ml
English: Eptifibatide Accord must not be used to treat patients with: - hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment - history of stroke within 30 days or any history of haemorrhagic stroke - known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm) - major surgery or severe trauma within past 6 weeks - a history of bleeding diathesis - thrombocytopenia (< 100,000 cells/mm3) - prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 - severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure
Danish: 6.1 - tegn på gastrointestinal blødning, kraftig genital/urinal blødning eller anden aktiv abnorm blødning inden for de sidste 30 dage før behandling - anamnese med apopleksi inden for 30 dage eller en hvilket som helst tidligere hjerneblødning - tidligere kendt sygdom inden for kraniet (neoplasi, arterio-venøs misdannelse, aneurisme) - større operation eller alvorligt traume inden for de seneste 6 uger - anamnese med blødningstendens - trombocytopeni (< 100.000 celler/mm3) - protrombintid > 1,2 gange kontrol eller International Normaliseret Ratio (INR) ≥ 2,0 - svær hypertension (systolisk blodtryk > 200 mm Hg eller diastolisk blodtryk > 110 mm Hg under antihypertensiv behandling) - svær nyreinsufficiens (kreatininclearance < 30 ml/minut) eller dialysepatienter - klinisk signifikant nedsat leverfunktion - samtidig eller planlagt indgift af en anden parenteral glykoprotein-(GP) IIb/IIIa-hæmmer.
English: Excipients: Citric acid monohydrate, sodium hydroxide, water for injections.
Danish: Hjælpestoffer: Citronsyremonohydrat, natriumhydroxid, vand til injektionsvæsker.
English: Package leaflet: Information for the patient Eptifibatide Accord 2 mg/ml solution for injection eptifibatide
Danish: Indlægsseddel: Information til patienten Eptifibatid Accord 2 mg/ml injektionsvæske, opløsning eptifibatid
English: Read the package leaflet before use.
Danish: Inspicer indholdet af hætteglasset før brug.
English: Thrombocytopenia.
Danish: Ikke almindelig Trombocytopeni.
English: How to store Eptifibatide Accord
Danish: Sådan får du Eptifibatid Accord
English: Eptifibatide Accord should not be used if it is noticed that particulate matter or discoloration is present.
Danish: Brug ikke Eptifibatid Accord, hvis der er bundfald eller misfarvning.
English: Package leaflet: Information for the patient Eptifibatide Accord 0.75 mg/ml solution for infusion eptifibatide
Danish: Indlægsseddel: Information til patienten Eptifibatid Accord 0,75 mg/ml infusionsvæske, opløsning eptifibatid
English: Eptifibatide Accord 2 mg/ml solution for injection: 10 ml vial, pack of one vial.
Danish: Eptifibatid Accord 2 mg/ml injektionsvæske, opløsning: 10 ml hætteglas, pakning med 1 hætteglas.
English: In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of 1.0 microgram/kg/min for the duration of therapy.
Danish: Hos patienter med moderat nedsat nyrefunktion (kreatininclearance ≥ 30-< 50 ml/minut) skal der gives en intravenøs bolusinjektion på 180 mikrogram/kg efterfulgt af 1,0 mikrogram/kg/minut i kontinuerlig infusion i resten af behandlingsperioden.
English: − The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections.
Danish: - Øvrige indholdsstoffer: citronsyre, natriumhydroxid og vand til injektionsvæske.
English: Eptifibatide Accord 0.75 mg/ml solution for infusion: 100 ml vial, pack of one vial.
Danish: Eptifibatid Accord 0,75 mg/ml infusionsvæske, opløsning: 100 ml hætteglas, pakning med 1 hætteglas.
English: Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder:
Danish: Indehaver af markedsføringstilladelsen:
English: Eptifibatide appeared to increase the risk of bleeding when administered with streptokinase in an acute myocardial infarction study.
Danish: I et akut myokardieinfarkt-studie syntes eptifibatid at øge risikoen for blødning ved indgift med streptokinase.
English: These may affect more than 1 in 10 people - minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding with surgical procedures).
Danish: Dette kan forekomme hos flere end 1 ud af 10 patienter - større eller mindre blødning (fx blod i urin eller afføring, i opkast eller i forbindelse med operation) - blodmangel (nedsat antal røde blodlegemer).
English: One 100 ml Type I glass vial, closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Danish: Et 100 ml Type I glas hætteglas, lukket med en butylgummiprop og forseglet med ”flip-off”aluminiumforsegling.
English: 2 mg/ml : 3.45 mg/ml (0.150 mmol/ml) sodium For the full list of excipients, see section 6.1.
Danish: Hjælpestof(fer), som behandleren skal være opmærksom på: 2 mg/ml: 3,45 mg/ml (0,150 mmol/ml) natrium Alle hjælpestoffer er anført under pkt.
English: One 10 ml Type I glass vial, closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Danish: Et 10 ml Type I glas hætteglas, lukket med en butylgummiprop og forseglet med ”flip-off”aluminiumforsegling.
English: In patients with severe renal impairment (creatinine clearance < 30 ml/min) administered 1microgram/kg/min , 80 % inhibition was achieved in more than 80 % of patients at 24 hours.
Danish: Hos patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/min) blev der opnået en hæmning på 80 % hos over 80 % af patienterne 24 timer efter administration af 1 mikrogram/kg/min.
English: With delayed provisional eptifibatide administration, the TIMI major events were 1.4 % vs 2.0 % in patients who received reduced dose and standard dose respectively (p=0.54).There were no notable differences observed with GUSTO severe bleeding rates.
Danish: Ved forsinket provisorisk eptifibatid var hyppigheden af TIMI major blødning 1,4 % versus 2,0 % hos patienter, der fik henholdsvis en nedsat dosis og standarddosis (p = 0,54).
English: Any unused medicine after opening should be thrown away.
Danish: Ikke anvendt lægemiddel samt affald heraf skal bortskaffes efter åbning i henhold til lokale retningslinjer.
English: Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Danish: Hver ml opløsning indeholder 0,75 mg eptifibatid.
English: - if you have had a brain tumour or a condition that affects the blood vessels around the brain.
Danish: (husk også at fortælle lægen, hvis du nogensinde har haft et slagtilfælde) - hvis du har haft en hjernetumor eller en tilstand, der påvirker blodkarrene omkring hjernen - hvis du har gennemgået en større operation eller er blevet alvorligt skadet inden for de sidste
English: Do not use if particulate matter or discolouration is present.
Danish: Anvend ikke præparatet ved tegn på bundfald eller misfarvning.
English: Eptifibatide Accord 2 mg/ml solution for injection
Danish: Eptifibatid Accord 2 mg/ml injektionsvæske, opløsning
English: Each ml of solution for injection contains 2 mg of eptifibatide.
Danish: Hver ml opløsning indeholder 2 mg eptifibatid.
English: Eptifibatide Accord inhibits platelet aggregation, but does not appear to affect the viability of platelets.
Danish: Trombocytopeni og immunogenicitet relateret til GP IIb/IIIa-hæmmere Eptifibatid Accord hæmmer trombocytaggregationen, men synes ikke at påvirke trombocytternes levedygtighed.
English: Since either repeat exposure with any GP IIb/IIIa ligand-mimetic agent (like abciximab or eptifibatide) or first-time exposure to a GP IIb/IIIa inhibitor may be associated with immune-mediated thrombocytopenic responses, monitoring is required, i.e. platelet counts should be monitored prior to treatment, within 6 hours of administration, and at least once daily thereafter while on therapy and immediately at clinical signs of unexpected bleeding tendency.
Danish: Da både gentagen eksponering for et stof, der efterligner en GP IIb/IIIa-ligand (såsom abciximab og eptifibatid), og første-gangs-eksponering for en GP IIb/IIIa-hæmmer, kan være associeret med immunmedieret trombocytopeni, er overvågning påkrævet.
English: If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or nurse.
Danish: Spørg lægen eller sundhedspersonalet, hvis du har spørgsmål til brugen af dette produkt.
English: One 10 ml vial contains 20 mg of eptifibatide.
Danish: Et 10 ml hætteglas indeholder 20 mg eptifibatid.
English: One 100 ml vial contains 75 mg of eptifibatide.
Danish: Et 100 ml hætteglas indeholder 75 mg eptifibatid.
English: Solution for infusion 1 vial of 100 ml
Danish: Infusionsvæske, opløsning 1 hætteglas med 100 ml
English: Eptifibatide Accord 2 mg/ml solution for injection eptifibatide
Danish: Eptifibatid Accord 2 mg/ml injektionsvæske, opløsning eptifibatid
English: Eptifibatide Accord 0.75 mg/ml solution for infusion
Danish: Eptifibatid Accord 0,75 mg/ml infusionsvæske, opløsning
English: Thrombocytopenia, including acute profound thrombocytopenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Danish: Efter markedsføring er der ved administration af eptifibatid observeret trombocytopeni inklusive akut, markant trombocytopeni (se pkt.
English: Eptifibatide Accord 0.75 mg/ml solution for infusion eptifibatide
Danish: Eptifibatid Accord 0,75 mg/ml infusionsvæske, opløsning eptifibatid
English: What you need to know before you are given Eptifibatide Accord 3.
Danish: Det skal du vide, før du begynder at få Eptifibatid Accord Sådan får du Eptifibatid Accord Bivirkninger